Herpes virus helicase-primase inhibitor, Amenamevir is available now! Amenamevir, also known as ASP2151, is a herpes virus helicase-primase inhibitor. Amenamevir was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Jul 3, 2017 and marketed as Amenalief
BYL719(cas 1217486-61-7) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, liitle or no effect on PI3Kβ/γ/δ. BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway.
评论
发表评论